Sunday, June 4, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

NIAID RFI – Deployable Clinical Research Support

by Global Biodefense Staff
July 24, 2014
Pandemic Influenza Research

The National Institute of Allergy and infectious Diseases (NIAID) Division of Clinical Research (DCR) is conducting market research on operational, logistical and scientific support services for establishment of collaborative clinical research programs.

NIAID DCR rapidly deploys administrative & technical research support resources to meet the external demands placed on NIAID to facilitate the conduct of time sensitive, high priority, global, collaborative clinical research. Fulfillment of this mission requires DCR to have the capacity to expeditiously carry out collaborative clinical research both domestically and internationally.

In recent years, the NIAID research portfolio has expanded considerably in response to new challenges such as bioterrorism and emerging and re-emerging infectious diseases. The DCR supports NIAID goals by providing administrative and management support which facilitates high quality clinical research in this challenging and expanding environment.

NIAID DCR is proactively anticipating the delegation of additional “special projects” which will demand that the DCR expeditiously establish collaborative clinical research programs in the domestic and international arenas. Requests for projects of this nature could emanate from sources such as the U.S. Congress, U.S. State Department, DHHS, NIH, or NIAID.

Examples of current NIAID DCR support and collaboration programs include:

  • Southeast Asia Infectious Disease Clinical Research Network
  • Infectious Disease Clinical Research Program (IDCRP) with DoD and USUHS
  • Phidisa: an HIV/AIDS research collaboration of the South African Department of Defense

Statements describing an organization’s capability to provide required administrative and technical services to support this mission are requested no later than August 5, 2014.

Further details are available under Solicitation Number: HHS-NIH-NIAID(AO)-SS-14-001. The anticipated period of performance will be for five years from the date of award.

Source: FBO.gov

Tags: BioterrorismNIAIDRFI

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
research team gathers in front of a window
CBRNE

UAMS Receives $3.4 Million to Study Radiation Injuries Caused by Nuclear Accidents and Bioterrorism

August 24, 2022
NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC